The recent COVID-19 pandemic resulted in the acceleration of the mRNA platform, and the excellent clinical results for safety and efficacy has launched mRNA as a major option for creating new vaccines. However, these vaccines have important limitations, including the ultra-cold chain storage requirements that limits global access., manufacturing cost, and limited duration of immune responses. There is a broad need to increase the accessibility and reduce the cost of manufacturing of mRNA-based vaccines.
VaxForm proposes to incorporate our formulation platform utilizing aluminum adjuvant particles to improve mRNA vaccines’ efficacy and stability. Preliminary data showed that the adjuvant can enhance mRNA protein expression up to two-fold by in vitro assays and stabilized the vaccine for 2 months at 4°C vs the non-adjuvanted vaccine that degraded to 30% efficacy.
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
VaxForm LLC
